19/09/2014 21:59:41 Free Membership Login

Xoma News (NASDAQ:XOMA)

DateTimeSource
Headline
07/30/20141:15PMGLOBEXOMA to Announce Second Quarter 2014 Financial Results and Host Webcast on August 7
BERKELEY, Calif., July 30, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Thursday, August 7, 2014, at 4:30 p.m. Eastern Daylight Time to discuss second quarter 2014 financial results and provide... More...>>
06/30/20144:01PMGLOBEXOMA Call Today at 4:30pm ET/1:30pm PT to Confirm Communication Plan for EYEGUARD(TM)-B Clinical Program
BERKELEY, Calif., June 30, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call today, Monday, June 30, 2014, at 4:30 p.m. Eastern time to confirm the communication plan for its EYEGUARD™-B clinical... More...>>
05/28/20143:00PMGLOBEXOMA to Present at the Jefferies Global Healthcare Conference
BERKELEY, Calif., May 28, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today John Varian, the Company's Chief Executive Officer, is scheduled to present at the Jefferies Global Healthcare Conference on June 3, 2014, at 2:00 p.m... More...>>
05/12/20143:30PMGLOBEXOMA to Present at the Bank of America Merrill Lynch Health Care Conference
BERKELEY, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today Paul Rubin, the Company's Senior Vice President, Research and Development & Chief Medical Officer, is scheduled to present at the Bank of America Merrill... More...>>
05/09/20144:00PMZACKSXOMA Posts Wider Q1 Loss - Analyst Blog
XOMA Corporation’s (XOMA) shares declined 18.5% after the company reported wider-than-expected loss per share in the first quarter of 2014 and slower-than-expected patient enrolment in two phase III studies being conducted with gevokizumab. The company posted a loss of 23 cents per share, wider than the Zacks Consensus... More...>>
05/07/20144:01PMGLOBEXOMA Reports First Quarter 2014 Operational Highlights and Financial Results
BERKELEY, Calif., May 7, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced its operational highlights and financial results for the first quarter ended March 31, 2014. First Quarter 2014 Operational Highlights Met with the U.S... More...>>
04/30/20141:25PMGLOBEXOMA to Announce First Quarter 2014 Financial Results and Host Webcast on May 7
BERKELEY, Calif., April 30, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Wednesday, May 7, 2014, at 4:30 p.m. Eastern time to discuss first quarter 2014 financial results and provide an update... More...>>
04/28/20149:00AMGLOBEXOMA Finalizes Plans for Gevokizumab Phase 3 Clinical Program in Pyoderma Gangrenosum
BERKELEY, Calif., April 28, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today that based on its meeting with the U.S Food and Drug Administration (FDA), the Company is finalizing its plans for a gevokizumab Phase 3 program in pyoderma... More...>>
03/19/20148:00AMPRNUSHealthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Or...
Healthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Orexigen Therapeutics, and XOMA Editor Note: For more information about this release, please scroll to bottom. PR Newswire NEW YORK, March 19, 2014 NEW YORK, March 19, 2014 /PRNewswire/ -- Today, Analysts... More...>>
03/06/201412:22PMPRNUSTechnical Roundup - Most Active: J. C. Penney, XOMA, BlackBerry and Nokia
Technical Roundup - Most Active: J. C. Penney, XOMA, BlackBerry and Nokia PR Newswire NEW YORK, March 6, 2014 NEW YORK, March 6, 2014 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. The trading session on Wednesday, March 05, 2014 ended on a mixed note as the Dow Jones Industrial... More...>>
03/04/20144:57PMGLOBEXOMA Reports 2013 Operational Highlights and Fourth Quarter and Full-Year 2013 Financial Results
BERKELEY, Calif., March 4, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced 2013 operational highlights and financial results for the fourth quarter and year ended December 31, 2013. 2013 Operational Highlights Announced the selection... More...>>
03/04/20144:36PMGLOBEXOMA Provides Update on Gevokizumab Proof-of-Concept Program
Results from two Phase 2 erosive osteoarthritis of the hand studies do not support movement to pivotal development FDA End of Phase 2 meeting for pyoderma gangrenosum indication scheduled for March 2014 Conference call to be held today at 6:00 p.m. Eastern / 3:00 p.m. Pacific BERKELEY, Calif., March 4, 2014 (GLOBE NEWSWIRE... More...>>
02/24/20146:20PMGLOBEXOMA Receives Orphan Drug Designation From U.S. FDA for Pyoderma Gangrenosum
BERKELEY, Calif., Feb. 24, 2014 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced today gevokizumab, the Company's IL-1 beta modulating antibody, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for... More...>>
01/14/20148:52AMZACKSSurging Earnings Estimates Signal Good News for XOMA Corporation (XOMA) - Tale of the Tape
Xoma Corporation (XOMA) is a developer of antibody-based therapeutics that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well. These positive earnings estimate revisions suggest... More...>>
12/18/20134:01PMGLOBEXOMA Announces Closing of the Offering and Exercise of Option
BERKELEY, Calif., Dec. 18, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) announced today the closing of the offering of 10,925,000 shares of its common stock, including 1,425,000 shares of common stock that were issued upon the exercise in full of the underwriters' option to purchase additional shares, at a price... More...>>
12/13/20139:13AMGLOBEXOMA Announces Pricing of Approximately $50.0 Million Offering of Common Stock
BERKELEY, Calif., Dec. 13, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) announced today the pricing of 9,500,000 shares of its common stock at a price to the public of $5.25 per share. In addition, XOMA has granted the underwriters a 30-day option to purchase up to an additional 1,425,000 shares of... More...>>
12/12/20134:05PMGLOBEXOMA Announces Proposed Public Offering of Common Stock
BERKELEY, Calif., Dec. 12, 2013 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq:XOMA) announced today it is offering to sell, subject to market and other conditions, shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. XOMA also expects to grant the underwriters... More...>>
12/03/20134:28AMZACKSPharma & Biotech Stock Outlook - Dec 2013 - Industry Outlook
With 2013 coming to an end, the worst of the patent cliff faced by the pharmaceutical sector is over. Major blockbuster drugs like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers Squibbs’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa... More...>>
12/03/20134:28AMZACKSPharma & Biotech Stock Outlook - Dec 2013 - Zacks Analyst Interviews
With 2013 coming to an end, the worst of the patent cliff faced by the pharmaceutical sector is over. Major blockbuster drugs like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers Squibbs’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa... More...>>
12/03/20134:28AMZACKSPharma & Biotech Stock Outlook - Dec 2013 - Zacks Analyst Interviews
With 2013 coming to an end, the worst of the patent cliff faced by the pharmaceutical sector is over. Major blockbuster drugs like Merck’s (MRK) Singulair, Pfizer’s (PFE) Lipitor, Forest Laboratories’ (FRX) Lexapro, Sanofi/Bristol-Myers Squibbs’ (SNY/BMY) Plavix and Eli Lilly’s (LLY) Zyprexa... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq xoma140919 21:59